Danica Pension Livsforsikringsaktieselskab Takes $15.24 Million Position in Danaher Corporation $DHR

Danica Pension Livsforsikringsaktieselskab bought a new position in shares of Danaher Corporation (NYSE:DHR) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 21,168 shares of the conglomerate’s stock, valued at approximately $15,242,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Danske Bank A S acquired a new stake in shares of Danaher in the second quarter worth $56,000. Diversify Advisory Services LLC acquired a new position in shares of Danaher during the 2nd quarter valued at $419,000. Gables Capital Management Inc. purchased a new stake in Danaher during the 2nd quarter worth $89,000. Wealthfront Advisers LLC purchased a new stake in Danaher during the 2nd quarter worth $7,109,000. Finally, Cypress Asset Management Inc. TX increased its holdings in Danaher by 5.9% in the 2nd quarter. Cypress Asset Management Inc. TX now owns 4,317 shares of the conglomerate’s stock valued at $3,108,000 after purchasing an additional 242 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of recent research reports. Royal Bank Of Canada boosted their price objective on Danaher from $200.00 to $215.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 22nd. HSBC decreased their price target on Danaher from $270.00 to $230.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. JPMorgan Chase & Co. decreased their target price on shares of Danaher from $275.00 to $245.00 and set an “overweight” rating for the company in a research note on Wednesday, April 22nd. Stifel Nicolaus cut their target price on Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a research report on Wednesday, July 22nd. Finally, Wells Fargo & Company decreased their price objective on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $228.91.

Danaher Stock Performance

Danaher stock opened at $211.92 on Thursday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80. The company has a fifty day moving average price of $194.30 and a two-hundred day moving average price of $192.44. The company has a market cap of $148.98 billion, a PE ratio of 37.64, a P/E/G ratio of 2.49 and a beta of 0.78.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. The business had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The business’s quarterly revenue was up 5.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.77 EPS. Research analysts expect that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.